← Back to Nuqta Atlas
Editorially curated · sa-shgp-pharmacogenomics
SHGP Population Pharmacogenomics Cohort
Characterized frequencies and potential clinical actionability of pharmacogenetic alleles in the Saudi population.
01 / Project overview
What the record establishes.
- Geographic scope
- 11,889 unrelated Saudi individuals
- Project type
- National population pharmacogenomics dataset; SHGP child project
- Research domain
- Pharmacogenetic variation and actionable alleles
- Years
- 2015–2019
- Lifecycle status
- completed
- Status basis
- Samples and data were generated during 2015-2019 and the primary population analysis was published in 2022.
- Status evidence date
- 2022-02-10
- Scale
- 1,928 participants tested on custom pharmacogenomic panels plus 9,961 exomes across eight pharmacogenes; 99.2% of panel-tested individuals carried at least one actionable allele.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Saudi Human Genome Program
- Partner organizations
- KACST-associated genome centers
- Organism / population
- Unrelated Saudi individuals sampled through SHGP genome centers
03 / Data and access
What exists and how it can be reached.
Data types
- custom pharmacogenomics panel
- whole-exome sequencing
- allele frequencies
Data access
Aggregate publication data public; individual-level data controlled
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Large SHGP-derived population dataset with an explicit sample count and actionable pharmacogenomic outputs.
Editorial note
SHGP child output, not a distinct national umbrella. Distinct from the KFSHRC clinical prescribing implementation program.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0